Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.
Snape MD, Kelly DF, Salt P, Green S, Snowden C, Diggle L, Borkowski A, Yu LM, Moxon ER, Pollard AJ. Snape MD, et al. Among authors: borkowski a. Clin Infect Dis. 2006 Dec 1;43(11):1387-94. doi: 10.1086/508776. Epub 2006 Oct 31. Clin Infect Dis. 2006. PMID: 17083009 Clinical Trial.
Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
de Whalley PC, Snape MD, Kelly DF, Banner C, Lewis S, Diggle L, John TM, Yu LM, Omar O, Borkowski A, Pollard AJ. de Whalley PC, et al. Among authors: borkowski a. Pediatr Infect Dis J. 2011 Nov;30(11):e203-8. doi: 10.1097/INF.0b013e318224fb14. Pediatr Infect Dis J. 2011. PMID: 21673612 Clinical Trial.
The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.
Blanchard Rohner G, Snape MD, Kelly DF, John T, Morant A, Yu LM, Borkowski A, Ceddia F, Borrow R, Siegrist CA, Pollard AJ. Blanchard Rohner G, et al. Among authors: borkowski a. J Immunol. 2008 Feb 15;180(4):2165-73. doi: 10.4049/jimmunol.180.4.2165. J Immunol. 2008. PMID: 18250423
Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.
Leroux-Roels G, Cramer JP, Mendelman PM, Sherwood J, Clemens R, Aerssens A, De Coster I, Borkowski A, Baehner F, Van Damme P. Leroux-Roels G, et al. Among authors: borkowski a. J Infect Dis. 2018 Jan 30;217(4):597-607. doi: 10.1093/infdis/jix572. J Infect Dis. 2018. PMID: 29140444 Free PMC article. Clinical Trial.
A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.
Treanor JJ, Atmar RL, Frey SE, Gormley R, Chen WH, Ferreira J, Goodwin R, Borkowski A, Clemens R, Mendelman PM. Treanor JJ, et al. Among authors: borkowski a. J Infect Dis. 2014 Dec 1;210(11):1763-71. doi: 10.1093/infdis/jiu337. Epub 2014 Jun 20. J Infect Dis. 2014. PMID: 24951828 Free PMC article. Clinical Trial.
Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.
Bernstein DI, Atmar RL, Lyon GM, Treanor JJ, Chen WH, Jiang X, Vinjé J, Gregoricus N, Frenck RW Jr, Moe CL, Al-Ibrahim MS, Barrett J, Ferreira J, Estes MK, Graham DY, Goodwin R, Borkowski A, Clemens R, Mendelman PM. Bernstein DI, et al. Among authors: borkowski a. J Infect Dis. 2015 Mar 15;211(6):870-8. doi: 10.1093/infdis/jiu497. Epub 2014 Sep 9. J Infect Dis. 2015. PMID: 25210140 Free PMC article. Clinical Trial.
333 results